DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Sonelokimab has also been assessed in a randomized, placebo-controlled third party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical ...

Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab), is expanded to the indications to include treatment of Crohn disease.

Imuldosa, formerly known as DMB-3115, is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adult and pediatric patients 6 years of age ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Most extensive LEO Pharma program to date at the European Academy of Dermatology and Venereology (EADV) congress featured an ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...

"They're both trying to out-moderate each other, which is interesting because you so seldom see a competition for the middle," New York-based Democratic strategist Jon Reinish told ABC News.

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...